Findings

What do systematic reviews say?

19 questions · 19 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 31.6%GRADE not reported 0 · 0%Very low 5 · 26.3%Low 7 · 36.8%Moderate 1 · 5.3%High 0 · 0%

Ginkgo biloba vs placebo

Tinnitus symptom severity · adults with tinnitus

1 finding from 1 review

Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 85 participants
Very low

Ginkgo biloba vs placebo

Serious adverse effects (bleeding or seizures) · adults with tinnitus

1 finding from 1 review

Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1154 participants
Low

Ginkgo biloba vs placebo

Tinnitus loudness · adults with tinnitus

1 finding from 1 review

Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Very low

Ginkgo biloba vs placebo

Health‐related quality of life · adults with tinnitus

1 finding from 1 review

Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

Ginkgo biloba vs placebo

Other adverse effects (gastrointestinal upset, headache, allergic reaction) · adults with tinnitus

Ginkgo biloba showed no clear difference in other adverse effects (gastrointestinal upset, headache, allergic… compared with placebo (low certainty).

1 finding from 1 review

Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
RR 0.91 [0.52, 1.6]
4 studies · 1175 participants
Low

Ginkgo biloba vs placebo

Tardive dyskinesia: No clinically important improvement · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

HERB ‐ GINKGO BILOBA probably leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (moderate certainty).

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 0.88 [0.81, 0.96]
1 study · 157 participants
Moderate

Ginkgo biloba vs placebo

Tardive dyskinesia: Deterioration of symptoms ‐ not reported · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ginkgo biloba vs placebo

Adverse effects ‐ not reported · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ginkgo biloba vs placebo

Leaving the study early · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether HERB ‐ GINKGO BILOBA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 0.25 [0.03, 2.22]
1 study · 157 participants
Very low

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Ginkgo biloba versus acetazolamide: risk of AMS · participants at risk of high altitude illness

The intervention may leads to lower ginkgo biloba versus acetazolamide: risk of AMS (low certainty).

1 finding from 1 review

Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 378 participants
Low

Intervention not reported

Acetazolamide + ginkgo biloba versus ginkgo biloba: risk of AMS · participants at risk of high altitude illness

The intervention may leads to lower acetazolamide + ginkgo biloba versus ginkgo biloba: risk of AMS (low certainty).

1 finding from 1 review

Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
RR 0.43 [0.26, 0.71]
1 study · 311 participants
Low

Intervention not reported

Acetazolamide + ginkgo biloba versus acetazolamide: risk of AMS · participants at risk of high altitude illness

The intervention showed no clear difference in acetazolamide + ginkgo biloba versus acetazolamide: risk of AMS (low certainty).

1 finding from 1 review

Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
RR 1.27 [0.65, 2.46]
1 study · 306 participants
Low

Intervention not reported

Ginkgo biloba versus placebo: risk of AMS · participants at risk of high altitude illness

The intervention may leads to lower ginkgo biloba versus placebo: risk of AMS (low certainty).

1 finding from 1 review

Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 504 participants
Low

Gingko biloba with concurrent intervention vs concurrent intervention only

Other adverse effects (gastrointestinal upset, headache, allergic reaction) · adults with tinnitus

The review found no eligible studies for this question.

1 finding from 1 review

Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gingko biloba with concurrent intervention vs concurrent intervention only

Tinnitus symptom severity · adults with tinnitus

1 finding from 1 review

Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Gingko biloba with concurrent intervention vs concurrent intervention only

Serious adverse effects (bleeding or seizures) · adults with tinnitus

The review found no eligible studies for this question.

1 finding from 1 review

Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gingko biloba with concurrent intervention vs concurrent intervention only

Tinnitus loudness · adults with tinnitus

1 finding from 1 review

Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Gingko biloba with concurrent intervention vs concurrent intervention only

Health‐related quality of life · adults with tinnitus

The review found no eligible studies for this question.

1 finding from 1 review

Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found